Biotech

All Articles

Ascendis' dwarfism medicine favorites in phase 3, intimidates BioMarin

.Ascendis Pharma has actually emerged as a potential danger to BioMarin's Voxzogo, mentioning stage ...

Despite ph. 3 skip, Alkeus views path ahead for eye illness possession

.Though Alkeus Pharmaceuticals' dental eye condition possession fell short to significantly lower ge...

Kairos goes public with $6M IPO to fund trials of cancer medicine

.With a triad of biotechs reaching the Nasdaq on Friday, it was actually very easy to skip a smaller...

Vaccine and Keytruda combination efficient in squamous cell cancer

.Immune system gate inhibitors are the superheroes of cancer cells therapy. Medications like Bristol...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our roundup of considerable management hirings, shooting...

Regeneron's Opdualag opponent presents 57% action cost

.Regeneron is actually back with long-lasting consequence for its own LAG-3 inhibitor and also PD-1 ...

AstraZeneca messages information on internal competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early examine the efficiency of its internal antibody-dru...

iTeos- GSK's TIGIT celebrity shows meaningful improvement

.After introducing a stage 3 launch based on positive midstage results, iTeos as well as GSK are las...

More collective FDA can speed up rare disease R&ampD: document

.The FDA should be much more open and also collective to release a surge in commendations of unusual...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It is actually an abnormally hectic Friday for biotech IPOs, with Zenas BioPharma, MBX as well as B...